Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome characterized by
volume overload, impaired exercise capacity, and recurrent hospital admissions. A major …

Background Controversy has persisted over the clinical benefits of low‐dose
sacubitril/valsartan in patients with heart failure (HF). Hypothesis Low‐dose …

Background Data about real-world effects of combined therapy with sacubitril/valsartan plus
dapagliflozin in patients affected by heart failure (HF) with reduced ejection fraction (HFrEF) …

Aims We tested the hypothesis that initiation versus non-initiation of sacubitril/valsartan is
associated with a more favorable subsequent change in left ventricular ejection fraction …

BACKGROUND: Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin
inhibitor (ARNI) that is now preferred in guidelines over angiotensin-converting enzyme …

Background: Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), has
demonstrated a survival benefit and reduces heart failure hospitalization in patients with …

Heart failure is an increasing public health issue with substantial morbidity and mortality
rates. This study aimed to evaluate the efficacy, safety, and long-term outcomes of …

Abstract Background Sacubitril/valsartan (S/V) improves outcomes in patients with heart
failure with reduced ejection fraction (HFrEF). Data about the immediate, short-, and …

Introduction: Heart failure is the third most common cause of death after coronary artery
disease and stroke. If we monitor the mortality of such a fatal disease, we can control the …

Introduction: Heart failure is an important leading cause of mortality and morbidity despite
optimal medical treatment and device therapy. Sacubitril/valsartan, a first-generation drug …